SPINACI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.465
EU - Europa 2.749
AS - Asia 1.496
SA - Sud America 211
Continente sconosciuto - Info sul continente non disponibili 186
AF - Africa 78
OC - Oceania 3
Totale 8.188
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.361
PL - Polonia 938
IT - Italia 642
SG - Singapore 502
CN - Cina 468
RU - Federazione Russa 427
BR - Brasile 151
GB - Regno Unito 149
DE - Germania 145
VN - Vietnam 142
HK - Hong Kong 128
FR - Francia 123
FI - Finlandia 74
UA - Ucraina 67
CA - Canada 62
KR - Corea 59
ZA - Sudafrica 50
SE - Svezia 46
JP - Giappone 41
IN - India 34
TR - Turchia 34
IE - Irlanda 29
NL - Olanda 27
MX - Messico 20
AR - Argentina 19
EC - Ecuador 16
AT - Austria 13
ES - Italia 13
BD - Bangladesh 12
BE - Belgio 12
TW - Taiwan 11
PK - Pakistan 10
CO - Colombia 9
CZ - Repubblica Ceca 9
AE - Emirati Arabi Uniti 8
CH - Svizzera 8
LT - Lituania 8
EG - Egitto 7
ID - Indonesia 7
IQ - Iraq 7
HN - Honduras 6
IR - Iran 6
EU - Europa 5
PE - Perù 5
LB - Libano 4
PH - Filippine 4
TN - Tunisia 4
UZ - Uzbekistan 4
VE - Venezuela 4
AU - Australia 3
JM - Giamaica 3
JO - Giordania 3
MA - Marocco 3
PY - Paraguay 3
TT - Trinidad e Tobago 3
AL - Albania 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CL - Cile 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
EE - Estonia 2
ET - Etiopia 2
IL - Israele 2
KE - Kenya 2
MY - Malesia 2
NG - Nigeria 2
NI - Nicaragua 2
RS - Serbia 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CM - Camerun 1
CR - Costa Rica 1
DM - Dominica 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
KH - Cambogia 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
ME - Montenegro 1
MU - Mauritius 1
MW - Malawi 1
PA - Panama 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SO - Somalia 1
SV - El Salvador 1
TH - Thailandia 1
UY - Uruguay 1
Totale 8.007
Salva come PNG Salva come JPEG
Città #
Warsaw 842
Ashburn 308
Fairfield 287
Singapore 263
San Jose 201
Council Bluffs 162
Chandler 160
Woodbridge 156
Houston 139
Camerino 131
Jacksonville 129
Seattle 116
Hong Kong 106
Beijing 102
Wilmington 100
Cambridge 94
Boardman 93
Kraków 93
Los Angeles 77
Ann Arbor 76
Dallas 75
New York 65
Helsinki 53
Johannesburg 46
Ho Chi Minh City 44
Edinburgh 43
Rome 43
Phoenix 40
St Louis 40
Munich 38
Seoul 38
Santa Clara 36
Tongling 33
Toronto 33
Frankfurt am Main 30
Guangzhou 29
Hanoi 29
London 29
Shanghai 29
Dublin 28
Lawrence 27
Nanjing 27
Princeton 27
Istanbul 25
Milan 25
Tokyo 25
Lauterbourg 24
The Dalles 24
Trieste 24
Ogden 23
Moscow 22
Centro 21
Ascoli Piceno 20
Chicago 20
San Mateo 20
São Paulo 20
Buffalo 18
San Francisco 17
Orem 16
Columbus 15
Dong Ket 15
San Diego 14
Denver 13
Brussels 12
Chennai 12
Atlanta 11
Manchester 11
Nanchang 11
Turku 11
Kunming 10
Montreal 10
Pescara 10
Hillsboro 9
Mexico City 9
Tampa 9
Brooklyn 8
Florence 8
Osimo 8
Poplar 8
Redondo Beach 8
Rio de Janeiro 8
Stockholm 8
Wuhan 8
Amsterdam 7
Boston 7
Chongqing 7
Dearborn 7
Fabriano 7
Guayaquil 7
Hangzhou 7
North Bergen 7
Nuremberg 7
Salt Lake City 7
Tianjin 7
Biên Hòa 6
Bremen 6
Brno 6
Broomall 6
Lakeland 6
Mason City 6
Totale 5.220
Salva come PNG Salva come JPEG
Nome #
A2AR agonists/A3R antagonists: design, synthesis, and biological evaluation of new ligands with dual activity 465
The Length and Flexibility of the 2-Substituent of 9-Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor 420
Pharmacological characterization of the GPR17 receptor dual profile 409
GPR17 receptor modulators and their therapeutic implications: review of recent patents 404
The G Protein-Coupled Receptor GPR17: Overview and Update 384
2′,3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 372
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications 369
2’,3’-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents 365
Simulation and Comparative Analysis of Different Binding Modes of Non-nucleoside Agonists at the A2A Adenosine Receptor 274
Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists 272
Approaches for designing and discovering purinergic drugs for gastrointestinal diseases 264
Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA 257
New substituted 9-propyladenine derivatives as A2Aadenosine receptor antagonists 244
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview 243
New sensible method to quantize the intestinal absorption of receptor ligands 231
A3 Adenosine Receptor Antagonists with Nucleoside Structures and Their Anticancer Activity 223
Modifications on the amino-3,5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity 198
A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? 192
Adenosine Receptors as Neuroinflammation Modulators: Role of A1 Agonists and A2A Antagonists 185
Adenine derivatives as inhibitors of the casein kinase CK1delta enzyme 183
A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders 173
Adenosine A3 receptor antagonists as anti-tumor treatment in human prostate cancer: an in vitro study 171
The Anti-Inflammatory and Pain-Relieving Effects of AR170, an Adenosine A3 Receptor Agonist, in a Rat Model of Colitis 158
New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases 156
Casein kinase 1delta inhibitors as promising agents for neurodegenerative disorders 156
Adenosine A2A Receptor Antagonists: Chemistry, SARs, and Therapeutic Potential 153
“Dual Anta-Inhibitors” of the A2A Adenosine Receptor and Casein Kinase CK1delta: Synthesis, Biological Evaluation, and Molecular Modeling Studies 148
Combined therapy of A1AR agonists and A2AAR antagonists in neuroinflammation 142
A patent review of adenosine A2B receptor antagonists (2016-present) 136
Inhibition of Prostate Cancer Cell Growth Using Antagonists of the Adenosine A3 Receptors 134
New A2A adenosine receptor antagonists: a structure-based upside-down interaction in the receptor cavity 112
Multipotent stromal cells from subcutaneous adipose tissue of normal weight and obese subjects: Modulation of their adipogenic differentiation by adenosine A1 receptor ligands 104
P2X3 Receptor Ligands: Structural Features and Potential Therapeutic Applications 101
A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment 74
Radioligands Targeting the Purinergic P2X Receptors 58
A2A Adenosine Receptor Antagonists and Their Efficacy in Rat Models of Parkinson's Disease 56
Structural Investigations on 2-Amidobenzimidazole Derivatives as New Inhibitors of Protein Kinase CK1 Delta 46
Beyond purinergic signaling: Dual ligand approaches to multitarget drug discovery 41
Adenine nucleotides as potent and selective GPR17 modulators 37
A Holistic Approach to Identifying a Positron Emission Tomography (PET) Tracer Candidate for In Vivo Imaging of Purinergic P2X7 Receptor in Neuroinflammation 23
Synthesis, radio-synthesis and in vitro evaluation of terminally fluorinated derivatives of HU-210 and HU-211 as novel candidate PET tracers 21
Benzamide derivatives as allosteric ligands of the human and rat P2X7 receptor 19
Synthesis and characterization of new P2X7 receptor antagonists as antitumor agents 15
Totale 8.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.589
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.589
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022273 0 0 0 8 9 12 35 32 41 41 50 45
2022/2023387 50 47 14 56 25 39 1 25 55 32 32 11
2023/2024398 21 23 27 23 18 27 21 43 55 20 24 96
2024/20251.458 72 25 93 68 71 73 201 321 143 87 119 185
2025/20262.454 126 134 196 345 274 162 349 229 189 190 168 92
2026/2027473 172 91 194 16 0 0 0 0 0 0 0 0
Totale 8.188